simcyp.com

GENERAL
META
HTML
LINK ANALYSIS
SERVER

Simcyp.com recives any estimated n/a unique visitors and n/a unique page views per day. Revenue gained from these much visits may be n/a per day from various advertising sources. The estimated worth of site is n/a.

Website Age n/a
Alexa Rank no-data
Country United States
IP Address 54.205.225.247

META INFORMATION

Title

Simcyp PBPK - Certara

Description

Keywords

Content Type

utf-8

No	Meta Name	Value
1	viewport	width=device-width, initial-scale=1, shrink-to-fit=no
2	robots	index, follow

GENERAL HTML INFORMATION

Type	Status
HTML 5
Responsive Website

HTML SIZE INFORMATION

Text / Code Ratio 12.93 %

simcyp.com has a website text/code ratio of 12.93 %. Search engine crawlers tend to not pick up pages with inadequate content.

IMPORTANT HTML TAGS AND COUNTS

Titles

H10
H29
H316
H40
H54
H60

No	Text
1	Featured product (2)
2	Featured (2)
3	Latest (2)
4	Latest news (2)
5	Get real answers from virtual pop****tions

No	Text
1	Phoenix™ pk/pd platform v 8.3 new (2)
2	Globalsubmit ectd submissions software (2)
3	Simcyp: 20 years of ınnovation (2)
4	Certara announces launch of pediatrics practice with scientific and regulatory experts (2)
5	Certara launches covıd-19 clinical outcomes database (2)
6	Simcyp™ pbpk simulator
7	Services
8	Software
9	Resources
10	Company
11	Subscribe for updates

No	Text
1	Simcyp timeline: 20 years of ınnovation
2	Simcyp consultancy: bespoke pbpk modeling and simulation
3	Application of pbpk modeling in drug discovery and development at pfizer
4	How to optimize your drug label using modeling and simulation technology

Text Styling

STRONG15
B0
EM2
I0
U0
CITE0

STRONG

No	Text
1	Simcyp Pediatric
2	Simcyp™ Consortium
3	Simcyp™ Animal
4	Manage drug-drug interactions (DDI): Unmanageable DDIs have led to the withdrawal of
5	numerous drugs. Simcyp PBPK models allow investigation of mDDIs due to compet**ive enzyme inhibition, mechanism-based inhibition, enzyme induction, and polypharmacy.
6	Accelerate formulation development: The Simcyp Simulator’s Advanced Dissolution Absorption and Metabolism (ADAM) model can be used for mechanistic IVIVC.
7	Inform dosing for special pop**tions: The FDA requires that clinical studies be conducted in certain special pop**tions (e.g., pregnant women, pediatrics). Ethnic groups and obese patients are worth considering, too.
8	An FDA draft guidance for industry, “Physiologically-based pharmacokinetic analyses—format and content” highlights the regulatory currency that PBPK now garners:
9	“Throughout a drug’s life cycle, PBPK model predictions can be used to support decisions on whether, when, and how to conduct certain clinical pharmacology studies, and to support dosing recommendations in product labeling.”
10	Recent projects by Certara’s Simcyp consultancy:
11	Designed a dosing regimen for a new oncology drug taking into account DDI interaction potential
12	Supported development of new and pediatric formulations
13	Developed a ‘virtual clinical PK package’ for a new chemical ent**y
14	Evaluated PK changes in specific and ‘special’ disease pop****tions
15	Evaluated the likelihood and magnitude of DDIs prior to clinical investigation

No	Text
1	clinical
2	“Throughout a drug’s life cycle, PBPK model predictions can be used to support decisions on whether, when, and how to conduct certain clinical pharmacology studies, and to support dosing recommendations in product labeling.”

LINK ANALYSIS

Total Link Count: 258

Internal Link Count : 242

No	Text	Type
1	Careers	text
2	-	image
3	Model-informed Drug Development	text
4	Services	text
5	Clinical Pharmacology	text
6	Drug Development and Regulatory Strategy	text
7	Model-based Meta Analysis	text
8	Pharmacometrics	text
9	Quant**ative Systems Pharmacology	text
10	Quant**ative Systems Toxicology and Safety	text
11	Simcyp Physiologically-based Pharmacokinetic Modeling	text
12	Virtual Bioequivalence	text
13	Software	text
14	PHOENIX™ PK/PD PLATFORM	text
15	SIMCYP™ PBPK SIMULATOR	text
16	Quant**ative Systems Pharmacology	text
17	Quant**ative Systems Toxicology and Safety	text
18	Cardiac Safety Simulator	text
19	Pirana Modeling Workbench	text
20	Simcyp In Vitro Data Analysis Toolkit (SIVA)	text
21	Trial Simulator	text
22	Training	text
23	Data and Informatics	text
24	CODEx and Clinical Trial Outcomes Databases	text
25	D360 Scientific Informatics Platform	text
26	Integral Data Repository	text
27	Featured Product Phoenix™ PK/PD Platform v 8.3 NEW	image
28	Regulatory and Access	text
29	Regulatory Science	text
30	GlobalSubmit eCTD Submissions Software	text
31	Medical and Regulatory Communications	text
32	Regulatory Affairs and Submission Strategy	text
33	Regulatory Operations	text
34	Regulatory Technology	text
35	Safety and Pharmacovigilance	text
36	Transparency and Disclosure	text
37	Evidence, Value and Access	text
38	BaseCase Value Communication Software	text
39	Decision Analytics and Modeling	text
40	Health Economics Outcomes Research	text
41	Health Outcomes Performance Estimator (HOPE)	text
42	Market Access and Pricing	text
43	Real World Evidence	text
44	US and EU Payer Engagement	text
45	US Managed Markets	text
46	Value Strategy	text
47	GlobalSubmit eCTD Submissions Software	text
48	Resources	text
49	Resources	text
50	Articles	text

External Link Count : 16

No	Text	Type
1	Support	text
2	Support	text
3	Support	text
4	Support	text
5	FDA draft guidance	text
6	Download brochure	text
7	Simcyp Timeline: 20 Years of Innovation Brochure	text
8	Simcyp Consultancy: Bespoke PBPK Modeling and Simulation Brochure	text
9	COVID-19 Resource Hub	text
10	COVID-19 Scientific Webinar Series	text
11	Support	text
12	-	empty
13	-	empty
14	-	empty
15	-	empty
16	日本語	text